Vanguard Global Advisers
LRMR icon

Vanguard Global Advisers’s Larimar Therapeutics LRMR Stock Holding History

Vanguard Global Advisers’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.2K Sell
21,047
-29,998
-59% -$119K ﹤0.01% 2976
2026
Q1 		$230K Buy
+51,045
New +$204K ﹤0.01% 2368

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Vanguard Global Advisers's LRMR Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Larimar Therapeutics (LRMR) stake by 59% in Q2 2026, selling an estimated $119K and leaving 21,047 shares worth $64.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

Vanguard Global Advisers first reported a position in LRMR in Q1 2026 and has held it in 2 quarters since. The position peaked at $230K in Q1 2026. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Vanguard Global Advisers held 21,047 shares of Larimar Therapeutics worth $64.2K as of Q2 2026.
  • Vanguard Global Advisers sold 29,998 Larimar Therapeutics shares in Q2 2026, an estimated $119K.
  • Larimar Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2976 holding.
  • Vanguard Global Advisers first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Larimar Therapeutics position peaked at $230K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.